Abstract
Toxicoproteomics is the study of the effects of chemical exposure on tissues through identification and quantitative evaluation of changes occurring in the proteome profile. This approach has been and continues to be applied in the preclinical testing of drugs for precise as well as high-throughput determination of toxic effects. Several investigations have indicated that use of proteomics can lead to successful identification of potentially toxic compounds earlier in the drug development process. This review covers recent studies that have used simultaneous measurement of multiple protein markers for prediction of tissue toxicities. In addition, conventional and newer proteomic techniques have been evaluated for applicability to drug toxicology studies. The potential of toxicoproteomics to predict adverse drug reactions in clinical use have also been explored.
Keywords: proteomics, toxicoproteomics, drug toxicology, personalized medicine, hepatotoxicity, nephrotoxicity
Current Proteomics
Title: Toxicoproteomics: Applications in Drug Development
Volume: 2 Issue: 2
Author(s): N. Gupta, A. Law, R. Poddar, M. Louie, A. Ray and D. N. Chakravarti
Affiliation:
Keywords: proteomics, toxicoproteomics, drug toxicology, personalized medicine, hepatotoxicity, nephrotoxicity
Abstract: Toxicoproteomics is the study of the effects of chemical exposure on tissues through identification and quantitative evaluation of changes occurring in the proteome profile. This approach has been and continues to be applied in the preclinical testing of drugs for precise as well as high-throughput determination of toxic effects. Several investigations have indicated that use of proteomics can lead to successful identification of potentially toxic compounds earlier in the drug development process. This review covers recent studies that have used simultaneous measurement of multiple protein markers for prediction of tissue toxicities. In addition, conventional and newer proteomic techniques have been evaluated for applicability to drug toxicology studies. The potential of toxicoproteomics to predict adverse drug reactions in clinical use have also been explored.
Export Options
About this article
Cite this article as:
Gupta N., Law A., Poddar R., Louie M., Ray A. and Chakravarti N. D., Toxicoproteomics: Applications in Drug Development, Current Proteomics 2005; 2 (2) . https://dx.doi.org/10.2174/1570164054494181
DOI https://dx.doi.org/10.2174/1570164054494181 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening Tyrosine Kinases and Inflammatory Signalling
Current Molecular Medicine MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Sigma-2 Receptor Ligands: Neurobiological Effects
Current Medicinal Chemistry The Toolbox of Designing Nanoparticles for Tumors
Mini-Reviews in Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry The Expression Patterns and Clinical Significance of microRNAs in Liver Diseases and Hepatocellular Carcinoma
Current Pharmaceutical Design Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets High Throughput Screening for Drug Discovery of Autophagy Modulators
Combinatorial Chemistry & High Throughput Screening Meet Our Editorial Board Member
Protein & Peptide Letters The Role of Unbound Drug in Pharmacokinetics/Pharmacodynamics and in Therapy
Current Pharmaceutical Design Serum Levels of IL-6, TNF-α and IL-10 as Early Predictors of Mortality in Trauma Hemorrhagic Shock Patients
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Novel Beta-Lactam Antibiotics Derivatives: Their New Applications as Gene Reporters, Antitumor Prodrugs and Enzyme Inhibitors
Mini-Reviews in Medicinal Chemistry Toxicity and Surface Modification of Dendrimers: A Critical Review
Current Drug Delivery SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Formulation and Application of Biodegradable Nanoparticles Based Biopharmaceutical Delivery - An Efficient Delivery System
Current Pharmaceutical Design New Trends in the Development of Transcription Factor Decoy (TFD) Pharmacotherapy
Current Drug Targets Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design The Biological Functions of NF-κB1 (p ) and its Potential as an Anti-Cancer Target
Current Cancer Drug Targets